FDA fast tracks Amgen myeloma treatment

The drugmaker ' s trial of its bispecific antibody for multiple myeloma found that seven out of ten patients given the second-highest dose of AMG420 responded to the drug
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news